Edition:
India

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

634.00INR
9:37am IST
Change (% chg)

Rs3.10 (+0.49%)
Prev Close
Rs630.90
Open
Rs632.10
Day's High
Rs636.00
Day's Low
Rs630.00
Volume
77,476
Avg. Vol
1,035,100
52-wk High
Rs972.95
52-wk Low
Rs525.85

Latest Key Developments (Source: Significant Developments)

Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864.  Full Article

Ligand Pharma And Glenmark Pharma Enter Into License Agreement
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS.LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​.  Full Article

Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Glenmark Pharmaceuticals Ltd ::LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Norethindrone Acetate, Ethinyl Estradiol Tablets
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS USP AND FERROUS FUMARATE TABLETS.  Full Article

Glenmark Pharmaceuticals Meets Primary Clinical Endpoint In Phase 3 Study Of Ryaltris
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS MET ITS PRIMARY CLINICAL ENDPOINT IN A PHASE 3 STUDY EVALUATING SAFETY OF RYALTRIS.SAYS RYALTRIS IS AN INVESTIGATIONAL FIXED-DOSE COMBINATION NASAL SPRAY, IN PERENNIAL ALLERGIC RHINITIS.TO FILE FIRST NDA TO US FDA FOR RYALTRIS IN THE FIRST QUARTER OF CY 2018.  Full Article

Glenmark Pharma Says Closed DCP For Generic Seretide Accuhaler In Nordic Region​
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Glenmark Pharmaceuticals Ltd ::ANNOUNCES CLOSURE OF DECENTRALISED REGISTRATION PROCEDURE (DCP) FOR GENERIC SERETIDE ACCUHALER IN NORDIC REGION​.  Full Article

Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS SAYS ‍BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017.GLENMARK PHARMACEUTICALS LTD <<>> SAYS ‍U.S. FDA ISSUED 7 OBSERVATIONS VIA FORM 483​​.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for HAILEY Fe 1/20 tablets ​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Glenmark Pharmaceuticals Ltd :Gets ANDA approval for HAILEY Fe 1/20 tablets ​.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for Haileytm 24 FE 1 mg/20 mcg​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Glenmark Pharmaceuticals Ltd :Gets ANDA approval for Haileytm 24 fe 1 mg/20 mcg​.  Full Article

India's Glenmark Pharmaceuticals Sept-qtr consol profit falls about 4 pct
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Glenmark Pharmaceuticals Ltd :Sept quarter consol profit 2.14 billion rupees versus profit of 2.24 billion rupees last year.Consensus forecast for Sept quarter consol profit was 2.10 billion rupees.Sept quarter consol net sales 22.23 billion rupees versus 21.73 billion rupees last year.  Full Article

BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864

* GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864 Source text - http://bit.ly/2mEqR6R Further company coverage: